Primary prevention
Currently, primary prevention for FMF patients is not indicated. Screening the general population for highly prevalent mutations in known genes involved in autoinflammatory disorders (autoinflammatory syndrome, FMF, tumor necrosis factor receptor-associated periodic syndrome, or hyperimmunoglobulinemia D syndrome) does not tend to yield additional relevant information.[60]
Secondary prevention
Colchicine is used as life-long prophylaxis to suppress attacks, to prevent amyloidosis, and to stabilize proteinuria in patients with amyloid nephropathy.[68][93] It is not usually used for asymptomatic patients (no clinical attacks, normal acute-phase reactants) even if FMF mutations have been identified. Family members of an index case with elevated acute-phase reactants and carrying the same mutation(s) as the symptomatic family member should receive colchicine treatment, as they may develop full FMF symptoms later in life and may be at risk for secondary amyloidosis.[104]
Use of this content is subject to our disclaimer